Trial Profile
Molecular profiling and safety study of operable lung cancer patients treated with Alimta [pemetrexed] combined with cisplatin as neoadjuvant chemotherapy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 17 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Jan 2011 Actual end date (Dec 2010) added as reported by ClinicalTrials.gov.
- 27 Apr 2010 Actual patient number (30) added as reported by ClinicalTrials.gov.